La Jolla Pharmaceutical Company To Present At The 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

Published: Feb 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - February 05, 2014) - La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City on February 10-11, 2014. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present on La Jolla's recent progress at 4:30pm Eastern Time on Monday, February 10, in the Conrad Room. The presentation will also be available via webcast on the Company's website at

About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. For more information on the Company please visit

Company Contact
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264


Chester S. Zygmont, III
Director of Finance
La Jolla Pharmaceutical Company
Phone: (858) 207-4262

Help employers find you! Check out all the jobs and post your resume.

Back to news